碳酸酐酶抑制剂舒噻美治疗睡眠呼吸暂停的随机对照试验
这项4周双盲、随机、安慰剂对照的剂量探索试验纳入不能耐受正压通气的中重度阻塞性睡眠呼吸暂停(OSA)患者,评估碳酸酐酶抑制剂舒噻美(STM)的安全性与耐受性。结果显示400 mg组和200 mg组均有间歇性感觉异常等不良反应,但无严重不良事件;STM显著降低呼吸暂停低通气指数(AHI),平均减少超过20事件/h。
要点
- STM在不能耐受正压通气的中重度OSA患者中安全性可接受,无严重不良事件。
- 400 mg组AHI从55.2降至33.0事件/h(-41.0%),200 mg组从61.1降至40.6事件/h(-32.1%)。
- 间歇性感觉异常在400 mg组、200 mg组和安慰剂组分别报告为79%、67%和18%。
核心结论
- STM在中重度OSA患者中显示出满意的安全性,平均减少AHI超过20事件/h,是药物试验中较强的降幅之一,支持开展更大规模临床研究。
研究设计与样本
- 4周双盲、随机、安慰剂对照的剂量探索试验,纳入不能耐受正压通气治疗的中度和/或重度OSA患者。
主要发现
- 400 mg组AHI从55.2降至33.0事件/h(-41.0%),200 mg组从61.1降至40.6事件/h(-32.1%),均P<0.001;安慰剂组从53.9降至50.9事件/h(-5.4%)。
- AHI下降≥50%的患者比例在400 mg组为40%、200 mg组为25%、安慰剂组为5%。
- 平均夜间血氧饱和度在400 mg和200 mg组均改善1.1%(分别P<0.001和P=0.034)。
- 患者相关结局指标无变化。
关键数值与推荐
- 间歇性感觉异常报告率:400 mg组79%(n=34)、200 mg组67%(n=12)、安慰剂组18%(n=22)。
- 400 mg组18%报告呼吸困难;高剂量组6例因不良事件退出;无严重不良事件。
临床怎么用
- STM可能作为不能耐受正压通气的中重度OSA患者的潜在药物治疗选择,但需关注感觉异常和呼吸困难等不良反应。
局限性
- 原文摘要未报告样本量之外的更多设计细节,且为4周短期剂量探索试验,患者相关结局未改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Current therapies for obstructive sleep apnea (OSA) are limited by insufficient efficacy, compliance, or tolerability. An effective pharmacological treatment for OSA is warranted. Carbonic anhydrase inhibition has been shown to ameliorate OSA. Objectives: To explore safety and tolerability of the carbonic anhydrase inhibitor sulthiame (STM) in OSA. Methods: A 4-week double-blind, randomized, placebo-controlled dose-guiding trial was conducted in patients with moderate and/or severe OSA not tolerating positive airway pressure treatment. Measurements and Main Results: Intermittent paresthesia was reported by 79%, 67%, and 18% of patients receiving 400 mg STM (n = 34), 200 mg STM (n = 12), and placebo (n = 22), respectively. Dyspnea was reported after 400 mg STM (18%). Six patients in the higher dose group withdrew because of adverse events. There were no serious adverse events. STM reduced the apnea-hypopnea index from 55.2 to 33.0 events/h (-41.0%) in the 400-mg group and from 61.1 to 40.6 events/h (-32.1%) after 200 mg (P < 0.001 for both). Corresponding placebo values were 53.9 and 50.9 events/h (-5.4%). The apnea-hypopnea index reduction threshold of ⩾50% was reached in 40% of patients after 400 mg, 25% after 200 mg, and 5% after placebo. Mean overnight oxygen saturation improved by 1.1% after 400 and 200 mg (P < 0.001 and P = 0.034, respectively). Patient-related outcomes were unchanged. Conclusions: STM showed a satisfactory safety profile in moderate and/or severe OSA. STM reduced OSA, on average, by more than 20 events/h, one of the strongest reductions reported in a drug trial in OSA. Larger scale clinical studies of STM in OSA are justified. Clinical trial registered with www.clinicaltrialsregister.eu (2017-004767-13).
引用
- Hedner J, Stenlöf K, Zou D, et al. A Randomized Controlled Clinical Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea. Am J Respir Crit Care Med. 2022. PMID: 35202553. doi:10.1164/rccm.202109-2043OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。